Lens Lab: the whole section

Essilor's Stellest made history in September 2025 when it became the first myopia-control spectacle lens authorized by the FDA. That "first" matters. It means the lens went through the agency's review process with clinical trial data the FDA found convincing — a bar no competitor had cleared before.

The FDA indication is specific: children ages 6–12 with myopia between −0.75 and −4.50 diopters. That's the population the trial data covers — outside that range, the evidence doesn't transfer automatically.

The numbers come from a two-year US clinical trial. Children wearing Stellest showed 71 percent less myopia progression and 53 percent less axial elongation compared to the control group. Axial elongation is the key metric — it's the physical lengthening of the eyeball that drives worsening nearsightedness. Slowing it by more than half is the kind of result that gets an entire industry's attention.

How does it work? Stellest uses a constellation of tiny lenslets — over a thousand of them — arranged across the lens surface. They create a volume of myopic defocus in front of the retina while the center of the lens corrects vision normally. The theory: that defocus signal tells the growing eye to slow down. Kids see clearly through the middle and get the treatment signal in the periphery, all day, just by wearing their glasses.

Stellest is the established, cleared, data-backed option in the US market. If you're an American parent hearing about myopia control for the first time, this is likely the name your eye doctor mentions first. There's a reason.

Talk to your eye doctor: Stellest is FDA-cleared, but clearance doesn't mean it's right for every child — ask if your kid is a candidate and what the follow-up schedule looks like.

Sources: AAO EyeNet — FDA authorization of Stellest.

Hoya's MiYOSMART has been fighting myopia since 2018 — more than 15 million lenses dispensed across 50-plus countries, and reimbursed by French health coverage since July 2025. That's the deepest real-world track record in the category. The new MiYOSMART iQ is the next generation, and its trial data turned heads at ARVO 2026 in Denver: 9 out of 10 children showed halted myopia progression at 12 months.

Halted — not slowed, stopped — at the one-year mark, for nine in ten kids in the trial. It's the most striking single data point in myopia control right now, and it's why the iQ launch is one of the biggest lens stories of 2026.

The technology is Hoya's Defocus Incorporated Multiple Segments — DIMS — a honeycomb of defocus segments surrounding a clear central zone for sharp vision. Same philosophy as its rivals: clear sight in the middle, growth-slowing signal at the edges, worn like ordinary glasses.

The catch for American parents: MiYOSMART iQ is rolling out in 2026 across Canada, China, Spain, Australia, and New Zealand — but not the US. Availability is a patchwork, and it changes. If you're outside the US, this may already be on your optician's shelf. If you're in the US, it's a name to know and a question to ask about the future.

Talk to your eye doctor: ask whether MiYOSMART iQ is available in your country, and if not, what comparable myopia management options exist locally.

Sources: HOYA — MiYOSMART iQ launch release.

You now know more about myopia control lenses than most people walking into an optical shop. Good. But knowledge isn't a prescription — your eye doctor's exam is. Here's how to make that appointment count. Bring these seven questions.

One: Is my child's myopia progressing, and how fast? Ask for the actual numbers — prescription change and axial length — not just "it's getting worse." Two: At this rate, where is it headed? Doctors can project based on age and progression curves. Three: Am I a candidate family for myopia management, or is standard correction the right call for now? Four: Which myopia control lenses are available here — Stellest, MiYOSMART iQ, MyoActive, or others — and how do you choose between them? Five: What does the evidence say for kids like mine — same age, similar prescription? Six: What's the follow-up schedule, and how will we know it's working? Seven: What does it cost, and does insurance or reimbursement cover any of it? In France, MiYOSMART has been reimbursed since July 2025 — coverage varies wildly everywhere else.

A few ground rules. Start early: myopia control works best when it begins while eyes are still growing. Be consistent: these lenses only work when worn. And be skeptical of anyone promising a cure — the honest word is "control," meaning slower, not stopped, and the trials measure averages, not guarantees.

You are your kid's advocate. The doctor is the expert. Bring the questions, hear the answers, decide together.

Talk to your eye doctor: print this page, bring it to the appointment, and work through all seven questions together.

Sources: AAO EyeNet — FDA authorization of Stellest; HOYA — MiYOSMART iQ launch release; ZEISS — MyoActive launch release.

The material inside your frames does more than change the price. It decides how thick your lenses look, how much they weigh on your nose, and whether they'll survive a face-first meeting with a tile floor. There are four materials that matter. Everything else is marketing noise.

CR-39 is the original. It's the basic plastic lens most of the world wore for decades — excellent optical clarity, easy to tint, and affordable. Its weakness is bulk: stronger prescriptions turn into thick, heavy edges, and it has no real impact resistance. It's perfectly fine for mild prescriptions in full-rim frames where the edges are hidden.

Polycarbonate was born for safety glasses and kids' eyewear. It's impact-resistant, thin, and light, which is why many opticians default to it. The trade-off is optical quality — it has the lowest Abbe value of the group, meaning colors can fringe at the edges in stronger prescriptions. Fine for most people, but not the crispest option on the shelf.

Trivex is the material insiders love. Developed for military helicopter windshields, it combines polycarbonate's toughness with CR-39's sharp optics, and it's lighter than both. If you want one material for an active life — sports, kids, general clumsiness — this is the sweet spot. Then there's high-index plastic, 1.67 and 1.74, engineered for strong prescriptions. It bends light more efficiently, so lenses come out dramatically thinner and flatter. It costs more and needs coatings to resist scratches, but past about ±4.00 it's the difference between lenses that look like glass and lenses that look like jar bottoms.

Your prescription strength decides the material. Your lifestyle decides the rest. Talk to your eye doctor about what your prescription actually needs.

Around age 40 to 45, the lens inside your eye stops flexing. Close-up text goes blurry while distance stays sharp — that's presbyopia, and it happens to everyone with a functioning birthday. Before progressives existed, the fix was bifocals: a visible line splitting the lens into distance on top and reading on the bottom, with nothing useful in between. Progressives solved that with a gradient.

A progressive lens has no line because the power changes smoothly from the top of the lens to the bottom. Look straight ahead and you're seeing through the distance prescription. Drop your eyes slightly and you're in the intermediate zone — computer screens, dashboards, the person across the dinner table. Look down and you're in the reading zone. One pair of glasses covers the whole day. That's the entire magic trick: a corridor of changing power, wider at the top, narrowing as it descends.

The corridor is also the catch. The sides of a progressive lens carry distortion — swim and sway at the periphery — because physics doesn't give gradients for free. This is why lens design matters so much. Older or budget progressives have narrow corridors and wide distortion zones; modern free-form digital progressives, surfaced point-by-point by computer-controlled lathes, widen the usable corridor significantly. The lens design tier you choose affects your vision more than the frame does.

Who are they for? Anyone with presbyopia who wants one pair of glasses instead of swapping between distance glasses and readers all day. They're also the default recommendation for first-time presbyopes who spend their days moving between screens and the real world. If you only need reading help and spend most of your day at a desk, occupational or office lenses — progressives tuned for intermediate and near — might serve you better. Talk to your eye doctor about which design fits your day.

Nobody tells you this at the fitting table: the first week in progressives is an adjustment period, not an instant upgrade. Your brain has to learn a new way of looking at the world, and brains are excellent at it — they just need about one to two weeks of consistent wear. The number one reason people "fail" at progressives is taking them off every time things feel strange. Wear them anyway. The technique is mostly that: don't take them off.

Days one through three feel the strangest. The periphery of the lenses will swim a little when you turn your head. Stairs and curbs may look like they're tilting, because you're catching them through the wrong part of the corridor. The fix is mechanical, not optical: point your nose at what you want to see instead of glancing sideways. Turn your head toward the thing, then move your eyes up or down within the lens to find the right zone. Distance up top, reading at the bottom. It feels deliberate at first. Then it becomes automatic.

By the end of week one, most wearers report the weirdness fading into the background. By week two, the head-turning habit is muscle memory and the glasses feel like glasses. A few realistic expectations: cheap or outdated progressive designs have narrower corridors, which means more head-turning forever — the lens tier matters. Frames that sit too low or slide down your nose will misalign the corridor with your eyes, which is why the fitting and adjustment at pickup is not optional small talk. And if after two to three weeks of full-time wear things still feel wrong — persistent double vision, headaches that don't fade, one eye clearly worse — go back. Sometimes the prescription needs a tweak, sometimes the fitting does.

Progressives are the most returned lens in optical, and almost never because the concept is wrong. It's the adaptation, the fitting, or the design tier. Get those three right and you'll forget they're there. Talk to your eye doctor if adaptation isn't progressing.

Photochromic lenses had a reputation problem, and it was earned. The old generation darkened slowly, faded even slower, and left you walking indoors wearing sunglasses like you'd forgotten where you were. The molecules did their job — they just did it at the speed of a committee meeting. The new generation is a different product wearing the same name.

Transitions GEN S is the current benchmark: darkens in 25 seconds or less, fades back to clear in under two minutes. That's fast enough that the indoor-sunglasses embarrassment is basically over. The chemistry responds to UV intensity, so the lenses scale their darkness to the actual light — full sun gets full tint, overcast gets a light shade, and they stay clear indoors. For people who move between inside and outside all day, it's the closest thing to a single pair that does everything.

Know the limits before you buy. Photochromics are activated by UV, and car windshields block UV — so they won't darken much behind the wheel. If you drive a lot, you still need dedicated sunglasses. They also don't get as dark as a true sunglass lens at peak sun, and extreme cold can slow the fade-back. None of this is a flaw; it's physics, and any honest optician will tell you the same.

What's next is already shipping, just not for prescriptions yet. Electrochromic sunglasses — lenses that change tint in about a second at the push of a button — arrived as a consumer non-Rx product in 2026, per optogrid.com. They're not ophthalmic grade yet, so your prescription can't ride along, but the direction is obvious: the gap between "sunglasses" and "regular glasses" keeps shrinking. For now, GEN S-class photochromics are the practical sweet spot — one pair, most situations, no swapping. Talk to your eye doctor about whether light-adaptive lenses suit your prescription.

High-index lenses do one thing: bend light more efficiently, so less material is needed to hit your prescription. The number — 1.67, 1.74 — is the refractive index. Higher number, thinner lens. Standard plastic sits around 1.50, so jumping to 1.67 cuts noticeable thickness, and 1.74 cuts more. But thinner is not automatically better, and the price jumps are real.

Here's the honest breakdown. For mild to moderate prescriptions (roughly up to ±3.00), high-index is mostly cosmetic — your lenses are already reasonably thin, and the money buys you millimeters. Between ±3.00 and ±6.00, 1.67 is the sweet spot: visibly thinner, lighter on the nose, worth it for most wearers. Past ±6.00, 1.74 earns its price — at those powers, standard lenses get genuinely thick and heavy, and high-index is the difference between glasses you wear and glasses you tolerate. One caveat: higher index means lower Abbe value, meaning slightly more chromatic fringe at the edges. Pair high-index with good anti-reflective coating and the trade-off mostly disappears.

But the cheapest thickness reduction isn't a material at all — it's the frame. Smaller lens openings mean thinner edges, because lens thickness grows with diameter. Round and oval shapes hide edge thickness better than big rectangles. Full rims conceal the edge entirely; rimless and semi-rimless put it on display. Center the prescription in the frame — decentration adds thickness — and consider aspheric designs, which flatten the curves and slim the profile further.

So the formula: right index for your power, small frame, full rim, aspheric design. Do all four and even a strong prescription can look like off-the-shelf glasses. Talk to your eye doctor about which index your prescription actually needs.